AMPLATZER PFO Occluder Post Approval Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1214 participants.

Also called NCT03309332

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 1,214 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03309332
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Germany, Italy, Portugal, Switzerland, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03309332. Allocation not applicable; no masking; primary purpose prevention. Start 2018-01-31 (actual); primary completion 2030-02-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
AMPLATZER PFO Occluder Post Approval Study
Acronym
PFO PAS
Condition
Stroke
Condition
Patent Foramen Ovale
Intervention (Device)
AMPLATZER™ PFO Occluder
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct03309332
Content hash
b6a70c9698798da0ff756d97c79e50365940652c6482e64c1ccd6ff38b975496